Sunshine Biopharma Inc. Amortization of Intangible Assets
Sunshine Biopharma Inc. (SBFM) reported Amortization of Intangible Assets of $37.76 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-04-03
- Sunshine Biopharma Inc. amortization of intangible assets for the quarter ending 2023-12-31 was $11.70K.
- Sunshine Biopharma Inc. amortization of intangible assets for the quarter ending 2023-09-30 was $10.80K.
- Sunshine Biopharma Inc. amortization of intangible assets for the quarter ending 2023-06-30 was $8.10K.
- Sunshine Biopharma Inc. amortization of intangible assets for the quarter ending 2023-03-31 was $7.85K.
- Sunshine Biopharma Inc. amortization of intangible assets for fiscal 2025 was $37.76K, a 50.97% decline from fiscal 2024.
- Sunshine Biopharma Inc. amortization of intangible assets for fiscal 2024 was $77.01K, a 100.30% increase from fiscal 2023.
- Sunshine Biopharma Inc. amortization of intangible assets for fiscal 2023 was $38.45K.
- Sunshine Biopharma Inc. amortization of intangible assets for fiscal 2021 was $58.92K, a 0.00% change from fiscal 2020.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $37.76K 10-K · filed 2026-04-03 | ||||
| 2024-12-31 | $77.01K 10-K · filed 2026-04-03 | ||||
| 2023-12-31 | $11.70K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $22.50K derived: sum of 2 quarters · filed 2025-04-01 | $30.59K derived: sum of 3 quarters · filed 2025-04-01 | $38.45K 10-K · filed 2025-04-01 | |
| 2023-09-30 | $10.80K 10-Q · filed 2023-11-13 | $18.89K derived: sum of 2 quarters · filed 2023-11-13 | $26.75K 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | $8.10K 10-Q · filed 2023-08-10 | $15.95K derived: sum of 2 quarters · filed 2023-08-10 | |||
| 2023-03-31 | $7.85K 10-Q · filed 2023-08-10 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $0.00 derived: sum of 2 quarters · filed 2022-03-21 | $0.00 derived: sum of 3 quarters · filed 2022-03-21 | $58.92K 10-K · filed 2022-03-21 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $58.92K 10-Q · filed 2021-11-09 | $58.92K derived: sum of 4 quarters · filed 2022-03-21 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $58.92K 10-Q · filed 2021-08-09 | $58.92K derived: sum of 3 quarters · filed 2022-03-21 | ||
| 2021-03-31 | $58.92K 10-Q · filed 2021-05-11 | $58.92K derived: sum of 2 quarters · filed 2022-03-21 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $58.92K 10-K · filed 2022-03-21 | $14.07K 10-K · filed 2021-03-30 | ||
| 2020-09-30 | $58.92K 10-Q · filed 2020-11-12 | ||||
| 2019-12-31 | $13.77K 10-K · filed 2021-03-30 | ||||
| 2018-12-31 | $14.36K 10-K · filed 2020-05-01 | $2.41K 10-K · filed 2019-04-12 | |||
| 2017-12-31 | $6.63K 10-K · filed 2019-04-12 | ||||
| 2016-12-31 | $60.73K 10-K · filed 2018-04-02 | $58.92K 10-K · filed 2017-04-17 | |||
| 2015-12-31 | $3.77K 10-K · filed 2017-04-17 | ||||
| 2014-12-31 | $0.00 10-K · filed 2016-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |